Company profile: Neuraxpharm
1.1 - Company Overview
Company description
- Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.
Products and services
- Finished Dosage Forms (FDFs): Engineers and fabricates finished dosage pharmaceuticals, primarily solid oral dosage forms, for CNS disorders and other therapeutic areas
- Research & Development Services: Develops active substances and pharmaceuticals, executes bioequivalence studies, and manages regulatory affairs to progress CNS therapeutics
- Pharmacovigilance: Delivers services to monitor the safety of medications and manage adverse drug reactions by Neuraxpharm.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neuraxpharm
Rodin Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for neurological disorders by applying insights of epigenetics, leveraging key epigenetic modulators of CNS function and privileged access to Proteros’ best-in-class structural biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rodin Therapeutics company profile →
Chestnut Medical
HQ: United States
Website
- Description: Provider of minimally invasive therapies and technologies for interventional neuroradiology, focused on improving outcomes and reducing complications in the treatment of neurovascular disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chestnut Medical company profile →
Noctrix Health
HQ: United States
Website
- Description: Provider of early-stage medical device development, focusing on creating a revolutionary therapy for a chronic illness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noctrix Health company profile →
Sage Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sage Therapeutics company profile →
Cynapsus Therapeutics
HQ: Canada
Website
- Description: Provider of healthcare, biotechnology, and pharmaceutical therapeutics focused on Parkinson's disease, developing non-injectable treatments including APL-130277, a fast-acting, easy-to-use sublingual thin film for on-demand management of OFF episodes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cynapsus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neuraxpharm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neuraxpharm
2.2 - Growth funds investing in similar companies to Neuraxpharm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neuraxpharm
4.2 - Public trading comparable groups for Neuraxpharm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →